论文部分内容阅读
概述：在阿尔茨海默氏病（Alzheimer’s disease, AD）的诊断中采用生物标志物已日益得到重视，但在临床实践中使用生物标志物的可行性和价值仍然是有限的。然而，AD临床和制药研究中生物标志物的使用也许可以证明对明确AD的病理基础是非常有用的，并有助于提高在有效预防和治疗措施下的早期识别。此外，新诊断标准的广泛采用将提高不同研究结果之间的可比性，并为使用meta 分析方法合并和比较不同研究的结果创造了可能性—— 这种分析能够明确回答关于 AD 的病因、病程、预防和治疗等基本问题。“,”Summary:The use of biomarkers in the diagnosis of Alzheimer’s disease (AD) has been increasingly emphasized, but the feasibility and value of using biomarkers in clinical pracitce remain limited. However, the use of biomarkers in clinical and pharmaceutical research about AD may prove quite useful in clarifying the pathology underlying AD and, thus, help in the early identification of effective preventive and therapeutic interventions. Moreover, wide adoption of the new diagnostic criteria will improve comparability of research results across studies, and, thus, allow for the combination and comparison of study results using meta-analytic techniques–the types of analyses needed to definitively answer fundamental quesitons about the eitology, course, preveniton, and treatment of AD.